NCT07117877View on ClinicalTrials.gov

Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

September 15, 2025

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions
Platinum Resistant Ovarian CancerPlatinum Refractory Epithelial Ovarian CancerOvarian Cancer (OvCa)
Interventions
DRUG

Etoposide Capsules

50 mg(25mg/pill, 2 pills at a time) orally, qd, days 1 to 14, per cycle

DRUG

Bevacizumab

7.5mg/kg, i.v, q3w

DRUG

Iparomlimab and Tuvonralimab (QL1706)

5mg/kg, i.v., q3w

Trial Locations (1)

200032

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER